DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS Russian patent published in 2017 - IPC C07D487/04 C07D209/52 C07D403/04 C07D221/04 C07D209/44 C07D217/06 A61K31/519 A61P37/06 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a heterocyclic compound of the formula (I) or to its enantiomer, a diastereomer and a mixture thereof and a pharmaceutically acceptable salt thereof, wherein A: CH or N; L: bond or C_1-2alkyl; R¹ is selected from hydrogen, C_1-4alkyl, heteroaryl, - (CH₂)_nC(O)OR¹⁵, -C(O)R¹⁵, -C(O)NR¹⁶R¹⁷, and -S(O)_mR¹⁵, where each of alkyl or heteroaryl is possible is substituted with 1-3 groups selected from halogen, hydroxy, cyano, C_1-2alkyl, C_1-2alkoxy, C₃cycloalkyl, C₆aryl, pyridine and - (CH₂)_nC(O)OR¹⁵; R² or R⁴ is independently selected from hydrogen and C_1-2alkyl; R or R³ is independently selected from hydrogen and halogen; R⁵ or R⁶ is independently selected from hydrogen and C_1-2alkyl; R⁷, R⁸, R⁹ or R¹⁰ is independently selected from hydrogen, C_1-2alkyl and hydroxyC_1-2alkyl; R¹¹, R¹², R¹³ or R¹⁴ is independently selected from hydrogen or R¹¹ and R¹² or R¹³ and R¹⁴ taken together form an oxo group; R¹⁵ is selected from C_1-4alkyl, C₃cycloalkyl, C₂alkenyl, C₆aryl and pyridine, wherein each of alkyl, cycloalkyl or heteroaryl is optionally substituted with 1 to 4 groups selected from halogen, hydroxy, cyano, C_1-4alkoxy, C₆aryl, tetrazole, -NR¹⁹R²⁰, -S(O)_mR¹⁸, -NHC(O)OR¹⁸ and -NHS(O)_mR¹⁸; R¹⁶ or R¹⁷ is independently selected from hydrogen, C_1-3alkyl and heteroaryl, wherein heteroaryl is optionally substituted by one selected from C_1-2alkyl, hydroxy, C_1-2alkoxy, C₃cycloalkyl, hydroxyC₁alkyl and-OR¹⁸; R¹⁸ is selected from C_1-4alkyl and hydroxyC_1-4alkyl; R¹⁹ or R²⁰ is independently selected from the group consisting of hydrogen; M is 0, 1 or 2; N is 0 or 1; P is 0, 1 or 2; Q is 0 or 1; S is 1 or 2; And t is 1 or 2. The invention also relates to particular intermediates, a process for the preparation of a compound of formula (I), a pharmaceutical composition based on it, the use of a compound of formula (I), a method for inhibiting JAK kinases, and a method for treating certain diseases of the immune system.

EFFECT: new heterocyclic compounds possessing the activity of JAK-kinase inhibitor have been obtained.

22 cl, 7 tbl, 158 ex